Clinical Trial Search

Primary: The Incidence of New Onset of Diabetes After Transplant (NODAT) 12 Months After Kidney Transplantation — 3; 1 Participants — p=0.87

Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants

Primary: Freedom From Insulin Therapy Post Transplant — 3; 4 Participants

Primary: 2-hour Oral Glucose Tolerance Test-derived Blood Sugar — 141.00; 165.22 mg/dL

Primary: Maximal Acute C-peptide Response to Glucose (ACRmax) — 1.06; 1.52; 1.29 ng/mL*min

Primary: Delayed Graft Function — 8; 12 participants

Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies

Primary: Percentage Time in Range 70-180 mg/dL by CGM — 77 percentage of CGM readings 70-180mg/dL

Primary: Insulin Independence. — 2 Participants

Primary: Study Period: Average Serum BG — 130; 111 mg/dL — p=0.003

Primary: Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) — 2.25 ml/min/1.73m2

Primary: Composite Criteria: Insulin Independence and Glycosylated Hemoglobin (HbA1c) Under 6.5% at One Year — 71 Percentage of patients

Primary: Dexcom G6 Accuracy Post Radiation Exposure by Clark Error Analysis (Zone A and B %) — 806; 1226; 704; 1715 Matched blood glucose readings — p=<0.05

Primary: The Number of Insulin-independent Subjects at Day 75 (± 5 Days) Following the First Islet Cell Transplantation — 4; 1 participants

Primary: The Number of Insulin-Independent Subjects at One Year Following Islet Cell Transplantation — 5 participants

Primary: Insulin Independence — 42; 45 percentage of participants

Primary: Mortality — 36 mortality rate

Primary: Measurement of Glycemic Control by HbA1c and Prevention of Severe Hypoglycemia — 3 participants

Primary: Event-Specific Survival Comparisons — 22; 8; 9; 1 Participants — p=0.01

Primary: The Primary Endpoint Will be Insulin Independence After 6 Months of Therapy. — 0.25 proportion of participants — p=< 0.05

Primary: Percentage of Patients With Grade II-IV Acute GvHD by Day +100 Following Transplant — 94.4 percentage of participants

Primary: Compare Efficacy and Safety of Two Vitamin D Supplements of These Doses in Normalizing Vitamin D Concentrations. — 8; 29 ng/ml

Primary: BPAR (Biopsy-proven Acute Rejection) Incidence During the First 12 Months Post-transplant — 1; 3 participants — p=0.32

Primary: Rejection of Liver Transplant — 17; 20 participants — p=0.709

Primary: Area Under the Stimulated C-peptide Curve (AUC) Mean Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 1 Year Visit — 0.834; 0.775 nmol/L — p=0.048

Primary: The Proportion of Insulin Free Patients 3 Years After the Last Islet Infusion — 4 participants

Primary: Insulin Independence With Both an HbA1c ≤ 6.5% and no Severe Hypoglycemic Events at 1 Year After the First Islet Transplant or a Reduction in HbA1c of at Least 1 Point…

Primary: Progression From Prediabetes to Diabetes — 0; 1 Participants

Primary: Percent of Participants That Achieved Insulin Independence With Adequate Control of Blood Glucose Levels at One Year Post Final Islet Transplantation. — 44; 14; 17; 14…

Primary: Change in Mixed-meal-stimulated Peak C-peptide Value (Via Mixed-meal Tolerance Test) After 12 Months of Insulin Pump Therapy, Compared With MDI. — 1.8; 3.1 ng/mL